Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and Eli Lilly: GlobalData - Express Pharma

The Biggest Obesity Deals of 2025: Pharma Giants' Strategic Investments

In the dynamic obesity market of 2025, pharmaceutical giants are aggressively pursuing new assets to maintain competitiveness as the landscape evolves. While Novo Nordisk and Eli Lilly currently dominate with their approved GLP-1s, many other companies are striving to introduce better drugs to the market. Despite facing setbacks as the market transitions past the peak hype of previous years, these leaders are investing heavily in research and de…

Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and Eli Lilly: GlobalData - Express Pharma

According to the GlobalData report, the global pharma industry reported 76 mergers and acquisitions (M&A) deals in May 2025, amounting to a total disclosed value of $6.96 billion. This figure marks a decline compared to the previous 12-month average from May 2024 to April 2025, which recorded 95 deals worth $12.4 billion. According to industry data, three major transactions contributed 59 per cent of the total deal value in May. GSK announced it…